Menu
Search
|

Menu

Close
X

Corium International Inc CORI.OQ (NASDAQ Stock Exchange Global Market)

13.24 USD
+0.25 (+1.92%)
As of 2:29 AM IST
chart
Previous Close 12.99
Open 13.05
Volume 51,157
3m Avg Volume 63,696
Today’s High 13.32
Today’s Low 12.71
52 Week High 13.93
52 Week Low 3.48
Shares Outstanding (mil) 35.74
Market Capitalization (mil) 396.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
32
FY16
33
FY15
41
EPS (USD)
FY18
-0.368
FY17
-1.667
FY16
-1.647
FY15
-1.515
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
13.08
5.77
Price to Book (MRQ)
vs sector
9.03
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
189.33
16.52
LT Debt to Equity (MRQ)
vs sector
189.13
12.22
Return on Investment (TTM)
vs sector
-57.92
14.43
Return on Equity (TTM)
vs sector
-228.55
16.13

EXECUTIVE LEADERSHIP

David Greenwood
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Peter Staple
President, Chief Executive Officer, Director, Since 2008
Salary: $447,294.00
Bonus: --
Robert Breuil
Chief Financial Officer, Since 2012
Salary: $356,757.00
Bonus: --
Parminder Singh
Chief Technology Officer, Vice President - Research & Development, Since 2012
Salary: $312,680.00
Bonus: --
Joseph Sarret
Chief Business Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

235 Constitution Dr
MENLO PARK   CA   94025-1108

Phone: +1650.2988012

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

SPONSORED STORIES